Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations.
Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, Miller K, Debruyne FMJ, Klotz L. · 2019
Read Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. by Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, Miller K, Debruyne FMJ, Klotz L. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6370592.txt.
Description
Crawford and co-authors present a review in Prostate Cancer and Prostatic Diseases on androgen-targeted therapy for prostate cancer. Blocking testosterone has long been the base treatment for advanced disease. Recent drug approvals and better hormone assays have changed how doctors aim and monitor that blockade.
Modern assays show surgical castration leaves testosterone near 15 ng/dL, far below the old 50 ng/dL cutoff. Trials link levels under 20 ng/dL with longer survival and slower progression. New drugs that block androgen signaling push hormone activity close to zero. The authors advise routine testosterone checks alongside PSA tests. They also discuss tailoring dose timing to each patient's risks and lifestyle.
Catalog record
| CREATOR | Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, Miller K, Debruyne FMJ, Klotz L. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 76 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |